Guardant Health is a precision oncology company focused on helping conquer cancer through use of its proprietary tests, data sets and analytics. Co.'s Guardant Health Oncology Platform is designed to utilize its capabilities in technology, clinical development, regulatory and reimbursement. Co. engages in the clinical liquid biopsy market with its tests. Co.'s Guardant360 test is a molecular diagnostic test measuring cancer-related genes, and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. Co. has launched its Guardant Reveal liquid biopsy-based tests for residual and recurring cancer to address the need in Stage II-III colorectal cancer. The GH YTD return is shown above.
The YTD Return on the GH YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether GH YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GH YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|